Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2022

View Archived Issues

PIK3C2B variants impact mTOR pathway and lead to lipid signaling-driven focal epilepsy

Cytokine promotes heart repair after infarct

Alpha-emitting radioimmunotherapy: using throrium-227 and antibody conjugates

CD47 blockade with 225Ac-anti-CD33 radioimmunoconjugate in acute myeloid leukemia

Magmas inhibition as new therapeutic strategy in medulloblastoma

Novel humanized mouse model of posterior fossa A ependymoma

New MRGPRX2 antagonists identified at Bioardis

Chengdu Baiyu Pharmaceutical describes G12C mutant GTPase KRAS inhibitors

2692372 Ontario, Dunad Therapeutics patent tubulin polymerization inhibitors

Anti-glypican-3 antibody-drug conjugates developed at Ardeagen

RP Scherer Technologies patents TROP-2-targeting antibody-drug conjugates

Studies explore asprosin as a target for treating binge eating

Lenire licenses VSN-16R from UCL for fragile X syndrome

Heterozygous mutations in TMEM163 cause hypomyelinating leukodystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...